• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Palatin Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/28/24 9:00:20 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PTN alert in real time by email
    ptn_8k.htm
    0000911216false00009112162024-06-272024-06-27iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act Of 1934

     

    Date of Report (Date of earliest event reported): June 27, 2024

     

    Palatin Technologies, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

     

    001-15543

     

    95-4078884

    (State or other jurisdiction

     

    (Commission

     

    (IRS employer

    of incorporation)

     

    File Number)

     

    identification number)

     

    4B Cedar Brook Drive, Cranbury, NJ

     

    08512

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant's telephone number, including area code: (609) 495-2200

     

    Not Applicable

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class

     

    Trading Symbol

     

    Name of Each Exchange

    on Which Registered

    Common Stock, par value $.01 per share

     

    PTN

     

    NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). 

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders.

     

    On June 27, 2024, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Proposal 1”), (2) ratification of the appointment of the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024 (“Proposal 2”), (3) approval of an amendment to the Company’s 2011 Stock Incentive Plan, as amended and restated, to increase the number of shares available for equity awards by 1,000,000 shares (“Proposal 3”), and (4) to advise the Company whether stockholders approve the compensation of the Company’s named executive officers for the fiscal year ended June 30, 2023 (“Proposal 4”).

     

    As of May 22, 2024 (the “Record Date”), the total number of outstanding shares entitled to vote at the Annual Meeting was: 16,136,649 shares of common stock, one vote per share and 4,030 shares of Series A Preferred Stock, with approximately 1.32 votes per share, for an aggregate of 5,333 votes.  The combined total of votes entitled to be cast at the Annual Meeting as of the Record Date was a total of 16,141,973 votes.  At the Annual Meeting, the total number of votes present in person or by proxy was 7,137,392. 

     

    Proposal 1.  Election of Directors. The stockholders elected the following seven directors to serve until the next annual meeting, or until their successors are elected and qualified, by the votes set forth below:

     

    Nominee

     

     

    FOR

     

     

    WITHHELD

     

    01) Carl Spana, Ph.D.

     

     

     

    1,456,961

     

     

     

    399,669

     

    02) John K.A. Prendergast, Ph.D.

     

     

     

    1,356,125

     

     

     

    500,505

     

    03) Robert K. deVeer, Jr.

     

     

     

    1,384,910

     

     

     

    471,720

     

    04) J. Stanley Hull

     

     

    1,396,471

     

     

     

    460,159

     

    05) Alan W. Dunton, M.D.

     

     

     

    1,435,758

     

     

     

    420,872

     

    06) Arlene M. Morris

     

     

    1,367,820

     

     

     

    488,810

     

    07)  Anthony M. Manning, Ph.D.

     

     

     

    1,473,920

     

     

     

    382,710

     

     

    Broker Non-Votes:

    5,280,762

    for each director

      

    Proposal 2.  Ratification of Appointment of Independent Registered Public Accounting Firm.  The stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2024, by the votes set forth below:

     

    For

     

     

    Against

     

     

    Abstain

     

     

    6,728,849

     

     

     

    345,561

     

     

     

    62,982

     

     

    Broker Non-Votes:  Not Applicable

     

    Proposal 3.  Approval of an Amendment to the Company’s 2011 Stock Incentive Plan to Increase the Number of Shares Available for Equity Awards by 1,000,000 Shares.  The stockholders approved the amendment to the Company’s 2011 Stock Incentive Plan to increase the number of shares available for equity awards by 1,000,000 shares, by the votes set forth below:

     

    For

     

     

    Against

     

     

    Abstain

     

     

    1,103,832

     

     

     

    722,486

     

     

     

    30,312

     

     

    Broker Non-Votes:  5,280,762

     

    Proposal 4: Advise the Company whether Stockholders Approve the Compensation of the Company’s Named Executive Officers for the fiscal year ended June 30, 2023. The stockholders voted to advise the Company that they do approve the compensation of the Company’s named executive officers, by the votes set forth below:

     

    For

     

     

    Against

     

     

    Abstain

     

     

    925,432

     

     

     

    664,821

     

     

     

    266,377

     

     

    Broker Non-Votes: 5,280,762

     

     
    2

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    PALATIN TECHNOLOGIES, INC.

     

     

     

     

     

    Date: June 28, 2024

    By:  

    /s/ Stephen T. Wills  

     

     

     

    Stephen T. Wills, CPA, MST

     

     

     

    Executive Vice President, Chief Financial Officer and Chief Operating Officer

     

     

     
    3

     

    Get the next $PTN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTN

    DatePrice TargetRatingAnalyst
    12/12/2025$60.00Buy
    Laidlaw
    12/3/2025$50.00Buy
    Alliance Global Partners
    11/24/2021$2.00 → $5.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PTN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Deveer Robert K Jr bought $10,180 worth of shares (100,000 units at $0.10), increasing direct ownership by 263% to 138,065 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    5/12/25 9:30:59 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deveer Robert K Jr bought $12,703 worth of shares (6,000 units at $2.12), increasing direct ownership by 17% to 40,845 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    4/11/24 4:45:17 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Spana Carl covered exercise/tax liability with 321 shares, decreasing direct ownership by 0.50% to 64,377 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    1/2/26 4:30:20 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T covered exercise/tax liability with 212 shares, decreasing direct ownership by 0.33% to 63,276 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    1/2/26 4:30:25 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive VP and CFO/COO Wills Stephen T sold $9,461 worth of shares (565 units at $16.74), decreasing direct ownership by 0.88% to 63,488 units (SEC Form 4)

    4 - PALATIN TECHNOLOGIES INC (0000911216) (Issuer)

    12/29/25 4:30:13 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

    Advancing differentiated MC4R-based obesity programs into clinical developmentMelanocortin-based obesity therapies targeting rare MC4R pathway disorders with a primary focus on hypothalamic obesity and Prader-Willi syndromeOral small-molecule MC4R agonist PL7737 progressing through IND-enabling toxicology studies, with IND submission and clinical trial initiation planned for the first half of 2026Next-generation selective peptide MC4R agonists designed for once-weekly subcutaneous dosing, with IND submission and clinical trial initiation planned for the second half of 2026Executed sublicensing of MC1R agonist PL9643 in January 2026, sharpening focus on core obesity portfolio while preserving

    2/17/26 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

    Significant progress on multiple fronts – obesity pipeline advancing towards the clinic, out-licensing collaboration, strengthened balance sheet, and reinstatement of NYSE American trading Melanocortin-based therapies for obesityPL7737 IND-enabling toxicology underway; IND submission and clinical trial initiation planned for the first half of 2026Next-generation selective peptide MC4R agonists designed for once-weekly subcutaneous dosing; IND submission and clinical trial initiation planned for mid-2026Research Collaboration, License and Patent Assignment Agreement with Boehringer Ingelheim for the treatment of retinal diseases in August 2025Received €2.0M ($2.3M) upfrontAchieved €5.5M ($6.5

    11/13/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option

    Trading of Palatin's common shares resumed trading on NYSE today, November 12, 2025, under the symbol "PTN" PRINCETON, N.J., Nov. 12, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced underwritten public offering of 2,795,384 shares of its common stock (or pre-funded warrants in lieu thereof), which included the full exercise of the underwriters' option to purchase 364,615 additional shares of common stock (or pre-funded warrants in lieu thereof).

    11/12/25 12:15:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Palatin Technologies with a new price target

    Laidlaw initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $60.00

    12/12/25 8:54:18 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alliance Global Partners initiated coverage on Palatin Technologies with a new price target

    Alliance Global Partners initiated coverage of Palatin Technologies with a rating of Buy and set a new price target of $50.00

    12/3/25 7:47:15 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Palatin Technologies with a new price target

    HC Wainwright & Co. reiterated coverage of Palatin Technologies with a rating of Buy and set a new price target of $5.00 from $2.00 previously

    11/24/21 6:07:03 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    SEC Filings

    View All

    SEC Form 10-Q filed by Palatin Technologies Inc.

    10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    2/17/26 9:30:26 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Palatin Technologies Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K/A - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    12/19/25 4:30:47 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Palatin Technologies Inc.

    10-Q - PALATIN TECHNOLOGIES INC (0000911216) (Filer)

    5/14/25 5:00:30 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Financials

    Live finance-specific insights

    View All

    Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update

    Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatideDatabase lock completedTopline data readout expected later this monthNovel 'next generation' selective MC4R long-acting peptide and an oral small moleculeMultiple clinical trials targeted in calendar year 2025For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including hypothalamic obesityPhase 2 clinical study of PL8177 oral formulation for the treatment of ulcerative colitis Topline data readout expected later this quarterTeleconference and Webcast to be held on February 13, 2025, at 11:00 AM ETCRANBURY, N.J., Feb. 13, 2025 /PRNewswire/ -

    2/13/25 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025

    CRANBURY, N.J., Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE:PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025, at 11:00 a.m. ET. The conference call will include a review of the company's operating results and an update on programs under development. Schedule for the Operating Results Press Release, Conference Call / Audio Webcast Q

    2/10/25 4:00:00 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results

    Obesity programs:Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatidePatient enrollment completed October 2024Topline results expected 1Q calendar year 2025Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small molecule compoundsGeneral obesity, weight loss management, and rare MC4R pathway diseases like hypothalamic obesityDry eye disease (DED) and other ocular programs, ulcerative colitis (UC), male sexual dysfunction, and diabetic nephropathy programs:Investment bank engaged as a

    11/14/24 7:30:00 AM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PTN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Palatin Technologies Inc. (Amendment)

    SC 13G/A - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/24 2:55:16 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Palatin Technologies Inc.

    SC 13G - PALATIN TECHNOLOGIES INC (0000911216) (Subject)

    2/14/23 1:19:39 PM ET
    $PTN
    Biotechnology: Pharmaceutical Preparations
    Health Care